Clinical Trials
19 trialsNCT03918252 2026-06-05
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05960773 2026-06-05
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT03935893 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT06477419 2026-05-28
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07602946 2026-05-22
SELECTmeso
University of Southampton
Phase 2 Not yet recruiting
NCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT00715611 2026-05-14
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07514793 2026-04-07
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
Fudan University
Phase 2 Not yet recruiting
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05730816 2025-11-21
MAGIC-AKI
Brigham and Women's Hospital
Phase 2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06057935 2025-07-22
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed